KCSA’s psychedelics and mental healthcare practice provides PR, social media, investor relations and capital markets fundraising support for clinical-stage, pre-commercial / commercial publicly traded / privately funded companies focused on leveraging psychedelic medicine to treat disorders of the central nervous system (CNS). Today, we represent nearly a dozen companies in this space, and focus exclusively on companies working towards a clinical, regulated offering to treat patients suffering from things like PTSD, depression, anxiety, addiction, etc.

For years, KCSA has leveraged our expertise in clinical and broad-based healthcare to support companies in this fast-evolved, yet nascent space. Our dedication to best-in-breed communications approach has allowed us to work with the leading organizations on the forefront of clinical research, as well as clinical application and commercialization of these molecules.

As we do with all our public companies clients, KCSA has developed the investment theses and corporate narratives for CNS-focused companies in order to position them as experts and thought leaders within large disease categories across their stakeholder groups.